secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001558370-23-018694
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO Q3 2023 net loss $8.7M; CHASE Phase 2b enrollment ongoing, topline data 2H 2024
--------------------------------------------------------------------------------

- Net loss $8.7M ($3.41 per share) vs net income $29.1M in Q3 2022 due to prior year gain on sale of commercial business.
- Cash and equivalents $56.1M at Sep 30, 2023; together with CIRM award funds expected to fuel operations into Q2 2025.
- CHASE Phase 2b trial of KPI-012 for PCED actively enrolling; topline safety and efficacy data targeted for 2H 2024.
- R&D expenses $5.6M (up $0.2M YoY); SG&A expenses $5.0M (down $4.5M YoY) after sale of commercial portfolio.
- No product revenues in Q3 2023; preclinical evaluation of KPI-014 for inherited retinal degenerative diseases initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/0001558370-23-018694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/kala-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer